期刊
CURRENT OPINION IN GASTROENTEROLOGY
卷 31, 期 4, 页码 296-302出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOG.0000000000000191
关键词
adalimumab; anti-TNF monoclonal antibodies; infection; inflammatory bowel disease; infliximab; malignancy
Purpose of review The treatment of inflammatory bowel disease (IBD) in the modern area has improved with more biological agents available. Although the efficacy of these drugs has been demonstrated, concerns about their safety profile have been raised, and new data have emerged in the past year. Recent findings New data regarding the safety profile of anti-TNF were published over the last year, with a better identification of patients at risk of infection, and specific recommendations for the prevention of infections. There is a mild increase in malignancy in patients receiving anti-TNF, mainly lymphoma and skin cancer, which seems mainly attributable to combination with thiopurines. Specific recommendations for management of pregnancy were published. Summary Biological treatments are effective and safe in the treatment of IBD, provided that the recommendations for their use and monitoring are followed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据